1. Home
  2. SITM vs BBIO Comparison

SITM vs BBIO Comparison

Compare SITM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SiTime Corporation

SITM

SiTime Corporation

HOLD

Current Price

$554.84

Market Cap

18.0B

Sector

Technology

ML Signal

HOLD

Logo BridgeBio Pharma Inc.

BBIO

BridgeBio Pharma Inc.

N/A

Current Price

$76.71

Market Cap

15.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SITM
BBIO
Founded
2003
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
18.0B
15.9B
IPO Year
2019
2019

Fundamental Metrics

Financial Performance
Metric
SITM
BBIO
Price
$554.84
$76.71
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
7
25
Target Price
$405.00
$86.33
AVG Volume (30 Days)
424.5K
2.0M
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
57.53
N/A
EPS
0.47
N/A
Revenue
$326,660,000.00
$502,076,000.00
Revenue This Year
$49.65
$89.45
Revenue Next Year
$27.77
$73.78
P/E Ratio
$1,176.06
N/A
Revenue Growth
61.16
126.26
52 Week Low
$222.77
$48.78
52 Week High
$901.81
$93.42

Technical Indicators

Market Signals
Indicator
SITM
BBIO
Relative Strength Index (RSI) 41.94 36.76
Support Level $511.40 $70.65
Resistance Level $591.13 $79.57
Average True Range (ATR) 34.15 2.32
MACD -11.03 -0.85
Stochastic Oscillator 8.97 13.88

Price Performance

Historical Comparison
SITM
BBIO

About SITM SiTime Corporation

SiTime Corp is a provider of Precision Timing solutions to the international electronics industry, providing the timing functionality needed for electronics to operate reliably and correctly. The Company's products are designed to address a wide range of applications across a broad array of end markets. The Company operates a fabless business model and leverages its international network of distributors to address the end markets it serves. The Company operates in one reportable segment related to the design, development, and sale of silicon timing systems solutions. It operates in Hong Kong, Taiwan, the United States, Singapore, and other regions, with the majority of revenue coming from Hong Kong.

About BBIO BridgeBio Pharma Inc.

BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.

Share on Social Networks: